TG Therapeutics, Inc
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders. Its commercial portfolio is anchored by BRIUMVI for relapsing forms of multiple sclerosis, alongside a research pipeline and external business development activities such as in-licensing and partnerships.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBRIUMVI, an anti-CD20 monoclonal antibody approved for relapsing forms of multiple sclerosis.
Research-stage programs and product candidates targeting B-cell diseases and immune disorders.
In-licensing, partnership, acquisition, and investment activities to expand the portfolio.
Tuotteet
Raportoitu · osuus liikevaihdosta- Products98,5 %
- Royalty0,9 %
- Other Revenue0,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
TG Therapeutics sells primarily into the multiple sclerosis treatment market, where prescribing physicians and healthcare systems determine adoption. The end users are adult patients with relapsing forms of MS, while access depends heavily on payors, specialty pharmacies, and infusion-site channels. For pipeline assets, the company’s counterparties are typically research, licensing, or commercialization partners rather than direct patients.
Neurologists and MS specialists who prescribe BRIUMVI based on efficacy, safety, and administration profile.
Adults with relapsing forms of MS who receive treatment through physician-directed care and infusion settings.
Commercial and government payors that determine formulary access, reimbursement, and patient affordability.
Licensing and collaboration counterparties for development, commercialization, and asset expansion.
Strategia
TG Therapeutics is focused on expanding BRIUMVI adoption in multiple sclerosis while advancing a pipeline in B-cell diseases. It also seeks to broaden its portfolio through in-licensing, partnerships, acquisitions, and investment opportunities that can complement its commercial infrastructure.
The marketed product is the core revenue driver and the basis for the company's commercial platform.
Pipeline assets can diversify the company beyond a single commercial product.
In-licensing and partnerships can add assets without building everything internally.
Maantiede
TG Therapeutics is headquartered in the United States and commercializes BRIUMVI in the U.S. and selected international markets through regulatory approvals outside the U.S. The company relies on a global outsourced manufacturing network, including Samsung Biologics and FUJIFILM Diosynth Biotechnologies, so its operating footprint extends beyond its home market even though sales are centered in the U.S. Geography matters because reimbursement, regulatory approval, and supply-chain execution differ across markets.
Riskit
TG Therapeutics faces the typical risks of a commercial-stage biotech company: market acceptance, payer coverage, regulatory scrutiny, and competition from larger pharmaceutical companies. Its reliance on third-party manufacturing and a small number of approved products also creates concentration and supply-chain risk, while future pipeline value depends on successful development and approval outcomes.
- Limited market acceptance of approved productsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Sales depend on physician, patient, and payor adoption in a crowded MS market.
Kohdistuu: BRIUMVI
- Competition in multiple sclerosisVaikutus: KorkeaTodennäköisyys: Kohtalainen
Competing anti-CD20 therapies and new mechanisms may reduce utilization of BRIUMVI.
Kohdistuu: MS franchise
- Dependence on third-party manufacturersVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company does not own manufacturing facilities and relies on contract partners for supply.
Kohdistuu: BRIUMVI and pipeline supply
- Regulatory and reimbursement pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Drug pricing, coverage decisions, and healthcare reform can reduce realized revenue.
Kohdistuu: U.S. and ex-U.S. commercialization
- Clinical development and approval riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Pipeline assets may not demonstrate sufficient efficacy, safety, or commercial value.
Kohdistuu: Development pipeline
Kirjanpito
Harkinnanvaraiset erätPharma sales are recorded net of rebates, chargebacks, discounts, and returns, which can materially change reported revenue.
Vaikutus: BRIUMVI sales
Third-party manufacturing and limited supply partners require estimates for inventory, purchase commitments, and reserves.
Vaikutus: Cost of sales and working capital
R&D costs are expensed as incurred, so trial timing can create volatility in operating results.
Vaikutus: Research and development expense
In-licensed or acquired assets may need impairment testing if expected commercial value changes.
Vaikutus: Balance sheet and earnings
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
TScan Therapeutics, Inc.
TCRX · Biological Products, (No Diagnostic Substances)
TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer.
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Päivitetty: 24.9.2026